Longboard Pharmaceuticals (Nasdaq:LBPH) - Cotización, noticias y análisis

Resumen de acción LBPH

Longboard Pharmaceuticals, Inc. es una empresa biofarmacéutica en fase clínica centrada en el desarrollo de medicamentos novedosos y transformadores para enfermedades neurológicas. Saber más

Análisis fundamental de LBPH
Puntuación del snowflake
Valoración	1/6
Crecimiento futuro	0/6
Rendimiento pasado	0/6
Salud financiera	6/6
Dividendos	0/6

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Los accionistas han sido diluidos sustancialmente en el último año

Alta volatilidad del precio de la acción en los últimos 3 meses

Se prevé que los beneficios disminuyan un promedio de 7.6% al año durante los próximos 3 años

+ 1 riesgos adicionales

Competidores de Longboard Pharmaceuticals, Inc.

Ligand Pharmaceuticals

NasdaqGM:LGND

US$2.3b

Wave Life Sciences

NasdaqGM:WVE

US$2.2b

Amphastar Pharmaceuticals

NasdaqGS:AMPH

US$2.1b

Belite Bio

NasdaqCM:BLTE

US$2.3b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Longboard Pharmaceuticals
Precios históricos de las acciones
Precio actual de la acción	US$59.91
Máximo en las últimas 52 semanas	US$59.95
Mínimo de 52 semanas	US$3.60
Beta	1.09
1Cambio en 1 mes	0.52%
Variación en 3 meses	70.20%
Cambio de 1 año	1,405.28%
3Variación en 3 años	954.75%
Variación en 5 años	n/a
Variación desde la OPV	259.82%

Noticias y actualizaciones recientes

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

Oct 15

My Strategy For Longboard Pharmaceuticals After Its Big Run

Aug 28

Recent updates

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

Oct 15

My Strategy For Longboard Pharmaceuticals After Its Big Run

Aug 28

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Jul 12

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

Mar 16

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Oct 03

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Dec 25

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

Sep 10

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

May 28

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Feb 11

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Oct 27

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Jun 12

Longboard Pharmaceuticals EPS beats by $0.29

May 10

Rentabilidad de los accionistas

	LBPH	US Pharmaceuticals	Mercado US
7D	0.3%	2.8%	2.2%
1Y	1,405.3%	11.8%	32.6%

Rentabilidad vs. Industria: LBPH superó a la industria US Pharmaceuticals, que obtuvo un rendimiento del 11.8% el año pasado.

Rentabilidad vs. Mercado: LBPH superó al mercado US, que obtuvo un rendimiento del 32.6% el año pasado.

Volatilidad de los precios

Is LBPH's price volatile compared to industry and market?
LBPH volatility
LBPH Average Weekly Movement	16.9%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Precio estable de las acciones: El precio de las acciones de LBPH ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de LBPH ha disminuido de 46% a 17% en el último año, pero sigue siendo superior al 75% de los valores de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2020	50	Kevin Lind	www.longboardpharma.com

Longboard Pharmaceuticals, Inc. es una empresa biofarmacéutica en fase clínica centrada en el desarrollo de medicamentos novedosos y transformadores para enfermedades neurológicas. La empresa desarrolla la bexicaserina (LP352), que ha completado el ensayo clínico de fase 1b/2a para el tratamiento de las convulsiones asociadas a las encefalopatías epilépticas y del desarrollo. También desarrolla LP659, un modulador del receptor S1P para el tratamiento de enfermedades neurológicas.

Resumen de fundamentos de Longboard Pharmaceuticals, Inc.

¿Cómo se comparan los beneficios e ingresos de Longboard Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de LBPH
Capitalización bursátil	US$2.33b
Beneficios(TTM)	-US$76.34m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-30.6x

Ratio precio-beneficio (PE)

¿Está LBPH sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de LBPH
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$76.34m
Beneficios	-US$76.34m

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.96
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado LBPH a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción LBPH

Análisis de riesgos

Competidores de Longboard Pharmaceuticals, Inc.

NasdaqGM:LGND

US$2.3b

NasdaqGM:WVE

US$2.2b

NasdaqGS:AMPH

US$2.1b

NasdaqCM:BLTE

US$2.3b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Longboard Pharmaceuticals Initiates Phase 3 DEEp Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

Langkawi Corporation entered into an Agreement and Plan of Merger to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.4 billion.

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

My Strategy For Longboard Pharmaceuticals After Its Big Run

Recent updates

Longboard Pharmaceuticals Initiates Phase 3 DEEp Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

Langkawi Corporation entered into an Agreement and Plan of Merger to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.4 billion.

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

My Strategy For Longboard Pharmaceuticals After Its Big Run

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) dropped from Russell Small Cap Comp Value Index

Longboard Pharmaceuticals, Inc. Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

Longboard Pharmaceuticals, Inc. Announces Positive Interim Results from Its Ongoing 52-Week Open-Label Extension of the Pacific Study Evaluating Bexicaserin (Lp352)

Price target decreased by 7.2% to US$41.75

New major risk - Shareholder dilution

Longboard Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

Insufficient new directors

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding from Farallon Capital Management, L.L.C.

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding from Farallon Capital Management, L.L.C.

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

New major risk - Revenue and earnings growth

Longboard Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Shareholder dilution

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $210 million.

Price target increased by 43% to US$28.67

Longboard Pharmaceuticals, Inc. Announces Positive Topline Data from the Pacific Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (Dees)

Longboard Pharmaceuticals Announces Initiation of First-In-Human Phase 1 Clinical Study of Lp659 in Adult Healthy Volunteers

New minor risk - Market cap size

New minor risk - Share price stability

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Longboard Pharmaceuticals, Inc. Completes Enrollment of Phase 1b/2a Pacific Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies

New major risk - Financial position

Price target decreased by 14% to US$17.00

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

High number of new and inexperienced directors

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Longboard Pharmaceuticals Announces Positive Topline Data from A Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

Price target decreased to US$19.74

Price target decreased to US$22.80

Longboard Pharmaceuticals, Inc., Annual General Meeting, May 24, 2022

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Longboard Pharmaceuticals Provides Corporate Update

Longboard Pharmaceuticals EPS beats by $0.29

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Longboard Pharmaceuticals, Inc.

0.0x

-30.6x

Beneficios e Ingresos